<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373395</url>
  </required_header>
  <id_info>
    <org_study_id>D-CLAG-ZJU</org_study_id>
    <nct_id>NCT04373395</nct_id>
  </id_info>
  <brief_title>Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Prospective, Single-arm, Multicenter, Exploratory Study to Evaluate the Efficacy and Safety of D-CLAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Tongde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinhua Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huizhou Municipal Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanhui Pharmaceuticals CO., LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety
      of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission (CR) rate</measure>
    <time_frame>Complete blood count recovery or 1 month after 1 course of D-CLAG regimen</time_frame>
    <description>Complete remission rate after 1 course of D-CLAG regimen</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>D-CLAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of D-CLAG regimen (Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D-CLAG</intervention_name>
    <description>Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor</description>
    <arm_group_label>D-CLAG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia (non-acute promyelocytic leukemia) must be diagnosed before
             enrollment. Diagnostic criteria refer to WHO (World Health Organization)
             classification.

          -  Refractory or relapsed AML: refractory is defined as the failure of CR after 2 courses
             of standard induced remission therapy (2 courses of idarubicin+cytarabine (IA) regimen
             or 1 course of IA regimen + 1 course of high dose cytarabine); Relapse is defined as
             the blast cells &gt;5% in bone marrow or presence of extramedullary leukemia for patient
             who achieved CR before.

          -  Age 18-70.

          -  Eastern cancer cooperation group (ECOG) ≤2.

          -  Creatinine clearance ≥30 mL/min (estimated glomerular filtration rate (eGFR) according
             to the Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD)
             formula).

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× upper limit of
             normal range (ULN), total bilirubin ≤2×ULN.

          -  Echocardiography (ECHO) showed left ventricular ejection fraction (LVEF)≥50%.

          -  Life expectancy &gt;8 weeks.

          -  Voluntarily sign the informed consent and understand and comply with the requirements
             of the study.

        Exclusion Criteria:

          -  White blood cell (WBC) &gt; 50 * 109 / L

          -  Patients who have received salvage treatment with D-CLAG.

          -  Current active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled
             hypertension, congestive heart failure, any grade 3 or 4 heart disease according to
             the New York heart association (NYHA) functional classification, or a history of
             myocardial infarction within 6 months prior to screening.

          -  Other serious diseases that may limit patient participation in the trial (e.g.
             progressive infections, uncontrolled diabetes).

          -  Pregnant or nursing women.

          -  Unable to understand or follow the research protocol or unable to sign the informed
             consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongxian Hu</last_name>
    <phone>+86-0571-87236476</phone>
    <email>huyongxian2000@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital,School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongxian Hu, Dr</last_name>
      <phone>15957162012</phone>
      <email>huyongxian2000@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>President of The First Affiliated Hospital, College of Medicine, Zhejiang University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

